MCID: HYP061
MIFTS: 55

Hypertrophic Cardiomyopathy malady

Categories: Genetic diseases, Rare diseases, Cardiovascular diseases, Metabolic diseases

Aliases & Classifications for Hypertrophic Cardiomyopathy

About this section

Aliases & Descriptions for Hypertrophic Cardiomyopathy:

Name: Hypertrophic Cardiomyopathy 10 21 12 65
Familial Hypertrophic Cardiomyopathy 10 45 22 23
Idiopathic Hypertrophic Subaortic Stenosis 45 23
Cardiomyopathy, Hypertrophic, Familial 36 65
Heritable Hypertrophic Cardiomyopathy 45 23
Hereditary Ventricular Hypertrophy 45 23
Asymmetric Septal Hypertrophy 45 65
 
Cardiomyopathy, Hypertrophic 36 24
Cardiomyopathy Hypertrophic Obstructive 47
Hypertrophic Obstructive Cardiomyopathy 10
Familial Asymmetric Septal Hypertrophy 23
Cardiomyopathy Familial Hypertrophic 45
Familial Hcm 45
Hcm 23

Classifications:



External Ids:

Disease Ontology10 DOID:11984
ICD1027 I42.1
ICD9CM29 425.1, 425.11
UMLS65 C0007194, C0949658, C0205700

Summaries for Hypertrophic Cardiomyopathy

About this section
NIH Rare Diseases:45 Familial hypertrophic cardiomyopathy (hcm) is an inherited heart condition characterized by thickening of the heart muscle. the thickening most often occurs in the muscle wall that separates the left and right ventricles from each other (interventricular septum). this may restrict the flow of oxygen-rich blood from the heart, or it may lead to less efficient pumping of blood. signs and symptoms can vary. while some people have no symptoms, others may have chest pain, shortness of breath, palpitations, lightheadedness, dizziness, and/or fainting. even in the absence of symptoms, familial hcm can have serious consequences such as life-threatening arrhythmias, heart failure, and an increased risk of sudden death. familial hcm may be caused by mutations in any of several genes and is typically inherited in an autosomal dominant manner. treatment may depend on severity of symptoms and may include medications, surgical procedures, and/or an implantable cardioverter-defibrillator (icd). last updated: 11/30/2015

MalaCards based summary: Hypertrophic Cardiomyopathy, also known as familial hypertrophic cardiomyopathy, is related to myh7-related familial hypertrophic cardiomyopathy and cardiomyopathy, familial hypertrophic. An important gene associated with Hypertrophic Cardiomyopathy is MYH7 (Myosin, Heavy Chain 7, Cardiac Muscle, Beta), and among its related pathways are Cardiomyocyte Differentiation through BMP Receptors and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. Affiliated tissues include heart, breast and lung, and related mouse phenotypes are cardiovascular system and muscle.

Disease Ontology:10 An intrinsic cardiomyopathy that has material basis in autosomal dominant inheritance and that is characterized by abnormal thickening (hypertrophy) of the heart without any obvious cause.

Wikipedia:68 Hypertrophic cardiomyopathy (HCM) is a primary disease of the myocardium (the muscle of the heart) in... more...

GeneReviews summary for NBK1768

Related Diseases for Hypertrophic Cardiomyopathy

About this section

Diseases in the Hypertrophic Cardiomyopathy family:

Cardiomyopathy, Hypertrophic, 20 Cardiomyopathy, Hypertrophic, 2
Cardiomyopathy, Familial Hypertrophic, 9 Cardiomyopathy, Familial Hypertrophic
Cardiomyopathy, Hypertrophic, 13 Cardiomyopathy, Hypertrophic, 8
Cardiomyopathy, Hypertrophic, 16 Cardiomyopathy, Hypertrophic, 18
Cardiomyopathy, Hypertrophic 6 Cardiomyopathy, Hypertrophic, 15
Cardiomyopathy, Hypertrophic, 12 Cardiomyopathy, Hypertrophic, 4
Cardiomyopathy, Hypertrophic, 10 Cardiomyopathy, Hypertrophic, 14
Cardiomyopathy, Hypertrophic, 11 Cardiomyopathy, Hypertrophic, 3
Cardiomyopathy, Hypertrophic, 25 Cardiomyopathy, Hypertrophic, 19
Cardiomyopathy, Hypertrophic, 7 Cardiomyopathy, Hypertrophic, 17
Calr3-Related Familial Hypertrophic Cardiomyopathy Jph2-Related Familial Hypertrophic Cardiomyopathy
Actc1-Related Familial Hypertrophic Cardiomyopathy Actn2-Related Familial Hypertrophic Cardiomyopathy
Cav3-Related Hypertrophic Cardiomyopathy Csrp3-Related Familial Hypertrophic Cardiomyopathy
Mybpc3-Related Familial Hypertrophic Cardiomyopathy Myh6-Related Familial Hypertrophic Cardiomyopathy
Myh7-Related Familial Hypertrophic Cardiomyopathy Myl2-Related Familial Hypertrophic Cardiomyopathy
Myl3-Related Familial Hypertrophic Cardiomyopathy Myoz2-Related Familial Hypertrophic Cardiomyopathy
Nexn-Related Familial Hypertrophic Cardiomyopathy Pln-Related Familial Hypertrophic Cardiomyopathy
Tcap-Related Familial Hypertrophic Cardiomyopathy Tnnc1-Related Familial Hypertrophic Cardiomyopathy
Tnni3-Related Familial Hypertrophic Cardiomyopathy Tnnt2-Related Familial Hypertrophic Cardiomyopathy
Tpm1-Related Familial Hypertrophic Cardiomyopathy Ttn-Related Familial Hypertrophic Cardiomyopathy
Vcl-Related Familial Hypertrophic Cardiomyopathy Hypertrophic Cardiomyopathy Due to Intensive Athletic Training
Fatal Congenital Hypertrophic Cardiomyopathy Due to Glycogen Storage Disease

Diseases related to Hypertrophic Cardiomyopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 881)
idRelated DiseaseScoreTop Affiliating Genes
1myh7-related familial hypertrophic cardiomyopathy34.5MYH7, TPM1
2cardiomyopathy, familial hypertrophic32.2ACTC1, CALR3, JPH2, MYBPC3, MYH6, MYH7
3cardiomyopathy, hypertrophic, 2531.1TCAP, TTN
4gastric cancer31.0TNNI3, TNNT2
5cleft lip31.0MYH6, MYH7
6endomyocardial fibrosis30.9CSRP3, MYH7
7neovascular glaucoma30.8MYH7, PTPN11, TNNI3, TNNT2
8fatal infantile hypertrophic cardiomyopathy due to mitochondrial complex i deficiency12.5
9hypertrophic cardiomyopathy due to intensive athletic training12.4
10mitochondrial hypertrophic cardiomyopathy with lactic acidosis due to mto1 deficiency12.4
11progressive sensorineural hearing loss-hypertrophic cardiomyopathy syndrome12.4
12fatal congenital hypertrophic cardiomyopathy due to glycogen storage disease12.4
13hypertrophic cardiomyopathy, midventricular, digenic12.4
14hypertrophic cardiomyopathy and renal tubular disease due to mitochondrial dna mutation12.4
15cardiomyopathy, hypertrophic, 1212.3
16calr3-related familial hypertrophic cardiomyopathy12.3
17familial hypertrophic cardiomyopathy with wolff-parkinson-white syndrome, prkag2-related12.3
18jph2-related familial hypertrophic cardiomyopathy12.3
19actc1-related familial hypertrophic cardiomyopathy12.3
20actn2-related familial hypertrophic cardiomyopathy12.3
21cav3-related hypertrophic cardiomyopathy12.3
22csrp3-related familial hypertrophic cardiomyopathy12.3
23mybpc3-related familial hypertrophic cardiomyopathy12.3
24myh6-related familial hypertrophic cardiomyopathy12.3
25myl2-related familial hypertrophic cardiomyopathy12.3
26myl3-related familial hypertrophic cardiomyopathy12.3
27myoz2-related familial hypertrophic cardiomyopathy12.3
28nexn-related familial hypertrophic cardiomyopathy12.3
29pln-related familial hypertrophic cardiomyopathy12.3
30tcap-related familial hypertrophic cardiomyopathy12.3
31tnnc1-related familial hypertrophic cardiomyopathy12.3
32tnni3-related familial hypertrophic cardiomyopathy12.3
33tnnt2-related familial hypertrophic cardiomyopathy12.3
34tpm1-related familial hypertrophic cardiomyopathy12.3
35ttn-related familial hypertrophic cardiomyopathy12.3
36vcl-related familial hypertrophic cardiomyopathy12.3
37congenital cataract-hypertrophic cardiomyopathy-mitochondrial myopathy syndrome12.3
38lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy12.3
39encephalopathy-hypertrophic cardiomyopathy-renal tubular disease syndrome12.3
40combined oxidative phosphorylation deficiency 1612.0
41deafness, autosomal dominant 2211.8
42mitochondrial complex v deficiency, mitochondrial 111.8
43mitochondrial complex v deficiency, mitochondrial 211.8
44cardiomyopathy, hypertrophic, 811.7
45cardiomyopathy, hypertrophic, 1011.7
46lipodystrophy, familial partial, 211.3
47cardiomyopathy, hypertrophic 611.3
48combined oxidative phosphorylation deficiency 2311.2
49combined oxidative phosphorylation deficiency 811.1
50combined oxidative phosphorylation deficiency 911.1

Graphical network of the top 20 diseases related to Hypertrophic Cardiomyopathy:



Diseases related to hypertrophic cardiomyopathy

Symptoms for Hypertrophic Cardiomyopathy

About this section

Drugs & Therapeutics for Hypertrophic Cardiomyopathy

About this section

Drugs for Hypertrophic Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 106)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DoxazosinapprovedPhase 45474191-85-83157
Synonyms:
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
74191-85-8
77883-43-3 (mesylate)
AC-11062
AC1L1FAT
AC1Q470P
AC1Q4EXN
AKOS001681453
BPBio1_000963
BRD-A13188892-066-03-3
BSPBio_000875
C06970
C23H25N5O5
CHEBI:4708
CHEMBL707
CID3157
CPD000097306
Cardura
Cardura XL
Cardura XL (TN)
Cardura-1
Cardura-2
Cardura-4
ChemDiv2_005017
D07874
D9815_SIGMA
DB00590
 
Doxazosin
Doxazosin (INN)
Doxazosin Mesylate
Doxazosin [INN:BAN]
Doxazosin mesilate
Doxazosin mesylate
Doxazosina
Doxazosina [Spanish]
Doxazosine
Doxazosine [French]
Doxazosinum
Doxazosinum [Latin]
HMS1383E01
HMS2090C20
I06-1346
IDI1_003732
L000738
LS-110228
Lopac0_000474
MolPort-001-684-491
NCGC00018158-06
NCGC00089775-02
Normothen
Oprea1_259518
Prestwick0_000858
Prestwick1_000858
Prestwick2_000858
Prestwick3_000858
SAM002589981
SPBio_002796
UK 33274
UK-33274
UNII-NW1291F1W8
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
doxazosin
2
Carvedilolapproved, investigationalPhase 415372956-09-32585
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
107741-96-8
72956-09-3
AB1004830
AC-1641
AC1L1E0B
Artist
Artist (TN)
Atlana Pharma brand of carvedilol
BM 14190
BM-14-190
BM-14.190
BM-14190
BRD-A10977446-001-04-8
BRD-A10977446-045-01-1
Bio-0014
C043211
C06875
C2260
C24H26N2O4
CHEBI:3441
CHEMBL723
CID2585
CPD000449280
Carvedilol
Carvedilol (JAN/USAN/INN)
Carvedilol [USAN:INN:BAN:JAN]
Carvedilolum
Carvedilolum [Latin]
Coreg
Coreg (TN)
Coreg CR
Coropres
Coropress
D00255
DB01136
DQ 2466
DQ-2466
Dibloc
 
Dilatrend
EG-P042
Eucardic
GlaxoSmithKline brand of carvedilol
HMS2051N03
HMS2089B09
HMS2093E12
HSDB 7044
I06-0064
I06-1477
KBio2_002145
KBio2_004713
KBio2_007281
KBio3_002323
KBioGR_001252
KBioSS_002145
Kredex
L001243
LS-121875
Lakeside brand of carvedilol
MLS000758299
MLS000759508
MLS001424092
MolPort-003-666-814
NCGC00167832-01
NCGC00167832-02
NCGC00167832-03
Querto
Roche brand of carvedilol
SAM001246736
SAM001247021
SK&F-105517
SKF 105517
SMR000449280
SPBio_001885
STK621453
Spectrum2_001673
Spectrum3_001182
Spectrum4_000636
Spectrum5_001436
Spectrum_001665
TL8005080
UNII-0K47UL67F2
carvedilol
carvedilol, (+-)-isomer
carvedilol, (R)-isomer
carvedilol, (S)-isomer
carvedilol, 14C-labeled
3
DobutamineapprovedPhase 410834368-04-236811
Synonyms:
(+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
34368-04-2
34368-04-2 (Parent)
4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
52663-81-7 (hydrochloride)
74753-15-4
74753-15-4 (hydrobromide)
AC1L1WFF
AC1Q7AD1
BPBio1_000489
BRD-A78322124-003-03-3
BSPBio_000443
C06967
CHEBI:4670
CHEMBL926
CID36811
D03879
DB00841
DL-Dobutamine
DL-dobutamine
Dobutamin
Dobutamina
Dobutamina [INN-Spanish]
Dobutamine
Dobutamine (USP/INN)
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
Dobutamine Hydrochloride
 
Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer
Dobutamine [USAN:BAN:INN]
Dobutamine [USAN]
Dobutamine [Usan:Ban:Inn]
Dobutamine [Usan]
Dobutamine hydrobromide
Dobutamine hydrochloride
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
EINECS 277-982-4
HMS2089K05
Inotrex
L001157
LS-174467
LY 81929
Lilly 81929
Lopac0_000365
NCGC00015321-05
NCGC00024629-02
NCGC00024629-03
Prestwick0_000352
Prestwick1_000352
Prestwick2_000352
Prestwick3_000352
Racemic-Dobutamine
Racemic-dobutamine
SPBio_002364
UNII-0WR771DJXV
UNII-3S12J47372
dobutamine
dobutamine(usp)
rac-Dobutamine
rac-dobutamine
racemic-Dobutamine
4
Ranolazineapproved, investigationalPhase 476142387-99-356959
Synonyms:
( -)-Ranolazine
(-)-Ranolazine
142387-99-3
95635-55-5
AC-1673
AC1L1M17
AC1Q5LYD
BRD-A97674275-001-01-9
BSPBio_002276
CHEMBL1404
CID56959
CVT-303
D05700
DB00243
HMS1922F16
HMS2090L09
HMS2093D21
I01-2008
I06-0160
KEG-1295
LS-187267
Latixa
Lopac0_001062
 
MLS002154149
MolPort-003-666-653
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
NCGC00015897-05
NCGC00095177-01
NCGC00095177-02
NCGC00095177-03
RAN D
RANOLAZINE
RS-43285
RS-43285-003
Ran4
Ranexa
Ranexa (TN)
Ranexa, Ranolazine
Ranolazine (USAN/INN)
Ranolazine 2HCl
Ranolazine Dihydrochloride
Ranolazine dihydrochloride
S1799_Selleck
SMR000857382
SPECTRUM1505366
UNII-A6IEZ5M406
ranolazine
5
Metoprololapproved, investigationalPhase 419337350-58-64171
Synonyms:
(+/-)-Metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol
1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol
1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol
3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
37350-58-6
51384-51-1
54163-88-1
AB00053499
AC-19022
AC1L1HKM
AstraZeneca Brand of Metaoprolol Tartrate
AstraZeneca Brand of Seloken
BRD-A03623303-045-02-0
Beatrolol
Beloc
Beloc Duriles
Beloc-Duriles
BelocDuriles
Betaloc
Betaloc Astra
Betaloc-Astra
BetalocAstra
Betalok
C07202
CCRIS 4198
CGP 2175
CGP-2175
CGP2175
CHEBI:6904
CHEMBL13
CID4171
D008790
D02358
DB00264
Dl-Metoprolol
Dutoprol
EINECS 253-483-7
EINECS 257-166-4
H 93 26
H 93-26
H 9326
HMS2090B15
 
HSDB 6531
I01-7125
I06-0125
Jsp006606
L000669
LOPRESSIDONE
LS-122450
Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate
Lopresor
Lopresoretic
Lopressor
Lopressor HCT
Meijoprolol
Metohexal
Metoprolol
Metoprolol (USAN/INN)
Metoprolol Succinate
Metoprolol Succinate extended-release
Metoprolol Tartrate
Metoprolol [USAN:INN:BAN]
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metoprololum [INN-Latin]
Metroprolol
MolPort-005-938-039
NCGC00021148-02
NCGC00021148-03
NCGC00021148-04
Novartis Brand of Metprolol Tartrate
Preblok
Prelis
Presolol
Selo-Zok
Seloken
Seloken AstraZeneca Brand
Selopral
Seroken
Spesicor
Spesikor
TOPROL-XL
Tartrate, Metoprolol
Toprol
Toprol XL
Toprol-XL
UNII-GEB06NHM23
dl-Metoprolol
metoprolol
6
Tadalafilapproved, investigationalPhase 4, Phase 2140171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
7
SpironolactoneapprovedPhase 41591952-01-7, 52-01-75833
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
496916-40-6
52-01-7
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
AB00513806
AC-4214
AC1L1L8Q
Abbolactone
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm Brand of Spironolactone
Alpharma Brand of Spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne Brand of Spironolactone
Azupharma Brand of Spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
Cardel Brand of Spironolactone
D00443
D013148
DB00421
Deverol
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona Alter
Espironolactona Mundogen
Espironolactona [INN-Spanish]
Euteberol
Flumach
Frumikal
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
HSDB 3184
Hormosan Brand of Spironolactone
I06-1970
Jenapharm Brand of Spironolactone
Jenaspiron
LS-118614
LT00772287
Lacalmin
Lacdene
Laractone
MLS001074672
MLS001333253
MLS001333254
MLS002153245
MLS002207058
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura Brand of Spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
 
NCGC00164397-02
NSC 150399
NSC150399
Nefurofan
Novo Spiroton
Novo-Spiroton
NovoSpiroton
Novopharm Brand of Spironolactone
Osyrol
Pfizer Brand of Spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche Brand of Spironolactone
S0260
S3378_SIGMA
SAM002264648
SC 9420
SC-9420
SC9420
SMR000471892
SNL
SPBio_002115
Sagisal
Searle Brand of Spironolactone
Sincomen
Spiractin
Spiresis
Spiretic
Spiridon
Spiro L.U.T.
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro-Tablinen
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono Isis
Spirono-Isis
Spironocompren
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone A
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Xenalon
ZINC03861599
betapharm Brand of Spironolactone
ct Arzneimittel Brand of Spironolactone
ct-Arzneimittel Brand of Spironolactone
spiro von ct
spironolactone
spironolattone
von ct, spiro
8
ChlorthalidoneapprovedPhase 45777-36-12732
Synonyms:
(+-)-Chlorthalidone
(+-)-Hygroton
1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
1-keto-3-(3'-Sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-oxo-3-(3-Sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(1-Hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-Hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine
3-(4'-chloro-3'-Sulfamoylphenyl)-3-hydroxyphthalimidine
3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
5-22-07-00602 (Beilstein Handbook Reference)
77-36-1
A3836/0162845
AB00051946
AC-11367
AC1L1ECB
AC1Q558X
BPBio1_000487
BRD-A26384407-001-05-3
BRN 0312295
BSPBio_000441
BSPBio_002017
C14H11ClN2O4S
C2775_FLUKA
C2775_SIGMA
CHEBI:3654
CHEMBL1055
CID2732
CPD000058635
Chlorothalidone
Chlorphthalidolone
Chlorphthalidone
Chlortalidone
Chlortalidone (JAN/INN)
Chlortalidonum
Chlortalidonum [INN-Latin]
Chlorthalidon
Chlorthalidone
Chlorthalidone (USP)
Chlorthalidone [USAN:INN:BAN]
Clodronic Acid
Clortalidona
Clortalidona [INN-Spanish]
Clortalidone
Clortalidone [DCIT]
D00272
D002752
DB00310
DivK1c_000731
EINECS 201-022-5
Famolin
G 33182
G-33182
HMS1569G03
HMS1920M09
 
HMS2091E12
HMS502E13
HSDB 3035
Higroton
Hydro-Long
Hygroton
Hygroton (TN)
I06-0208
IDI1_000731
Igroton
Isoren
KBio1_000731
KBio2_000626
KBio2_003194
KBio2_005762
KBio3_001237
KBioGR_001574
KBioSS_000626
LS-31408
MLS000069531
MolPort-002-736-049
NCGC00094616-01
NCGC00094616-02
NCGC00094616-03
NCGC00094616-04
NINDS_000731
NSC 69200
NSC69200
Natriuran
Oksodolin (oxodolin)
Oradil
Oxodolin
Oxodoline
Phthalamodine
Phthalamudine
Prestwick0_000351
Prestwick1_000351
Prestwick2_000351
Prestwick3_000351
Prestwick_759
Racemic chlorthalidone
Renon
SAM002589983
SMR000058635
SPBio_000058
SPBio_002362
SPECTRUM1500187
ST088141
STK686335
Saluretin
Spectrum2_000099
Spectrum3_000349
Spectrum4_000957
Spectrum5_000743
Spectrum_000146
Tenoretic
Thalitone
Thalitone (TN)
UNII-Q0MQD1073Q
Urolin
Zambesil
chlorthalidone
9
GlimepirideapprovedPhase 422193479-97-13476
Synonyms:
1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
64598P
93479-97-1
AB00513874
AC-476
AC1L1G0T
Amarel
Amaryl
Amaryl (TN)
Amaryl, Glista OD, Glimepiride
Avaglim
BPBio1_000751
BRD-K34776109-001-03-4
BRD-K42693031-001-01-8
BRN 5365754
BSPBio_000681
Bio-0049
C07669
C24H34N4O5S
CAS-93479-97-1
CCRIS 7083
CHEBI:5383
CHEMBL1481
CID3476
CPD000466368
D00593
DB00222
Endial
G2295_SIGMA
Glimepirid
Glimepirida
Glimepirida [Spanish]
Glimepiride
Glimepiride (JAN/USP/INN)
Glimepiride [USAN:BAN:INN]
Glimepiridum
 
Glimepiridum [Latin]
Glimepride
Glimer
Glim├ępiride
Glymepirid
HMS1570C03
HMS2052L03
HMS2090K18
HOE 490
Hoe-490
I06-0029
I06-2285
LS-136752
MLS000759495
MLS001076674
MLS001401419
MolPort-003-847-587
MolPort-003-987-461
MolPort-005-941-721
NCGC00016960-01
NCGC00161404-01
NCGC00161404-02
NCGC00181757-01
Novo-glimepiride
Oprea1_382896
PMS-glimepiride
Prestwick0_000651
Prestwick1_000651
Prestwick2_000651
Prestwick3_000651
Ratio-glimepiride
Roname
S1344_Selleck
SAM001246710
SMR000466368
SPBio_002602
Sandoz glimepiride
Solosa
TL8005924
UNII-6KY687524K
ZINC00537791
glimepiride
10
EmpagliflozinapprovedPhase 493864070-44-0
Synonyms:
 
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
11Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 4, Phase 31804
12Hypolipidemic AgentsPhase 4, Phase 32228
13Adrenergic beta-AntagonistsPhase 4, Phase 3979
14Anticholesteremic AgentsPhase 4, Phase 31732
15AntimetabolitesPhase 4, Phase 39454
16Calcium, DietaryPhase 4, Phase 2, Phase 34678
17Immunologic FactorsPhase 4, Phase 218483
18Protective AgentsPhase 4, Phase 15651
19Contraceptives, OralPhase 4, Phase 3, Phase 2, Phase 13734
20Diuretics, Potassium SparingPhase 41445
21Sodium Channel BlockersPhase 41180
22Adrenergic beta-AgonistsPhase 41266
23Immunosuppressive AgentsPhase 4, Phase 210422
24Adrenergic AgonistsPhase 42331
25Adrenergic AgentsPhase 4, Phase 34204
26Atorvastatin CalciumPhase 4, Phase 3714134523-03-8
27Neurotransmitter AgentsPhase 4, Phase 314795
28Vasodilator AgentsPhase 4, Phase 2, Phase 32926
29diureticsPhase 41194
30Adrenergic alpha-AntagonistsPhase 4586
31Adrenergic AntagonistsPhase 4, Phase 31253
32Anti-Arrhythmia AgentsPhase 4, Phase 3, Phase 22371
33Antihypertensive AgentsPhase 4, Phase 2, Phase 33618
34Adrenergic beta-1 Receptor AntagonistsPhase 4, Phase 3292
35Hormone AntagonistsPhase 410002
36Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 218510
37Adrenergic alpha-1 Receptor AntagonistsPhase 4405
38Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 49988
39HormonesPhase 4, Phase 111748
40Natriuretic AgentsPhase 4, Phase 11403
41Phosphodiesterase 5 InhibitorsPhase 4, Phase 2513
42MineralocorticoidsPhase 4301
43Sodium Chloride Symporter InhibitorsPhase 4399
44Phosphodiesterase InhibitorsPhase 4, Phase 21062
45Mineralocorticoid Receptor AntagonistsPhase 4284
46Hypoglycemic AgentsPhase 44503
47carnitineNutraceuticalPhase 4146
48
LosartanapprovedPhase 3, Phase 2276114798-26-43961
Synonyms:
(2-Butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol
(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol
114798-26-4
124750-99-8 (mono-potassium salt)
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl-1H-imidazole-5-methanol
2-N-Butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5ylphenyl)benzyl]imidazole-5-methanol
2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole
2-n-butyl-4-chloro-5-hydroxymethyl-1-[[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]methyl]imidazole
AC1L1H3Q
BIDD:GT0286
BRD-K76205745-001-02-5
BSPBio_002695
C07072
C22H23ClN6O
CHEBI:6541
CHEMBL191
CID3961
CL23623
Cozaar
D08146
DB00678
DUP 89
DuP 89
DuP-753
HMS1922J13
HMS2093E22
Hyzaar
I14-9710
Jsp001094
KBio2_002193
 
KBio2_004761
KBio2_007329
KBio3_001915
KBioGR_001611
KBioSS_002193
L000351
LOSARTAN POTASSIUM
LS-78746
Lacidipine
Lortaan
Losartan
Losartan (INN)
Losartan Potassium
Losartan [INN:BAN]
Losartan monopotassium salt
Losartic
Losartic (TN)
MK-954
MK954
MolPort-003-666-553
NCGC00095125-01
NCGC00095125-02
NCGC00095125-03
Oprea1_644635
SPBio_001893
SPECTRUM1504268
Spectrum2_001677
Spectrum3_000998
Spectrum4_001126
Spectrum5_001466
Spectrum_001713
UNII-JMS50MPO89
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
losartan
losartan potassium
49
PerhexilineapprovedPhase 2, Phase 376621-47-24746
Synonyms:
(+)-2-(2,2-Dicyclohexylethyl)piperidine
(-)-2-(2,2-Dicyclohexylethyl)piperidine
2-(2,2-Dicyclohexylethyl)piperidine
39648-47-0
39648-48-1
6621-47-2
AB00053656
AC1L1IV5
BPBio1_000212
BSPBio_000192
BSPBio_003118
C19H35N
CHEBI:35553
CHEMBL75880
CID4746
D010480
D08340
DB01074
DivK1c_000542
EINECS 229-569-5
EINECS 254-558-7
EINECS 254-559-2
IDI1_000542
KBio1_000542
KBio2_000353
KBio2_002921
KBio2_005489
 
KBio3_002618
KBioGR_000685
KBioSS_000353
LS-176505
MolPort-003-808-309
NINDS_000542
Oprea1_365504
PERHEXILINE
Perhexilene
Perhexilina
Perhexilina [INN-Spanish]
Perhexiline
Perhexiline (INN)
Perhexiline [INN:BAN]
Perhexilinum
Perhexilinum [INN-Latin]
Perhexilline
Prestwick0_000286
Prestwick1_000286
Prestwick2_000286
Prestwick3_000286
SPBio_001358
SPBio_002411
Spectrum2_001539
Spectrum3_001579
Spectrum4_000173
Spectrum5_001084
Spectrum_000013
perhexilline
50
AtenololapprovedPhase 39929122-68-72249
Synonyms:
( inverted question mark)-Atenolol
(+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide
(+-)-Atenolol
(+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide
(1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
(?)-Atenolol
1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol
2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid
2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide
2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide
2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide
2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide
2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide
29122-68-7
4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide
4-[2 -Hydroxy-3 -(isopropylamino)-propoxy]phenylacetamide
4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide
60966-51-0
A 7655
A7655_SIGMA
AC-11142
AC1L1D99
AC1Q1QBX
AKOS005111050
ARONIS23884
Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)
Aircrit
Alinor
Altol
Anselol
Antipressan
Apo-Atenolol
Atcardil
Atecard
Atehexal
Atenblock
Atendol
Atenet
Ateni
Atenil
Atenol
Atenol 1A Pharma
Atenol 1A pharma
Atenol AL
Atenol Acis
Atenol Atid
Atenol CT
Atenol Cophar
Atenol Fecofar
Atenol GNR
Atenol Gador
Atenol Genericon
Atenol Heumann
Atenol MSD
Atenol NM Pharma
Atenol Nordic
Atenol PB
Atenol Quesada
Atenol Stada
Atenol Tika
Atenol Trom
Atenol Von CT
Atenol acis
Atenol ct
Atenol von ct
Atenol-Mepha
Atenol-Ratiopharm
Atenol-Wolff
Atenol-ratiopharm
Atenolin
Atenolol
Atenolol (JAN/USP)
Atenolol (JP15/USP/INN)
Atenolol [USAN:BAN:INN:JAN]
Atenolol [USAN:INN:BAN:JAN]
Atenololum
Atenololum [INN-Latin]
Atenomel
Atereal
Aterol
BB_SC-1519
BIM-0050109.0001
BRD-A20239487-001-02-5
BRN 2739235
BSPBio_002915
Betablok
Betacard
Betasyn
Betatop GE
Betatop Ge
Blocotenol
Blokium
CCRIS 4196
CHEBI:2904
CHEMBL24
CID2249
CPD000036768
Cardaxen
Cardiopress
Corotenol
Cuxanorm
D001262
D00235
DB00335
DivK1c_000057
Duraatenolol
Duratenol
 
EINECS 249-451-7
EINECS 262-544-7
EU-0100121
Evitocor
Farnormin
Felo-Bits
HMS1569L13
HMS1921H09
HMS2090I19
HMS2092D19
HMS500C19
HSDB 6526
Hipres
Hypoten
I01-3572
ICI 66,082
ICI 66082
ICI-66082
ICI66082
IDI1_000057
Ibinolo
InChI=1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
Internolol
Jenatenol
Juvental
KBio1_000057
KBio2_001844
KBio2_004412
KBio2_006980
KBio3_002415
KBioGR_000790
KBioSS_001844
L000116
LS-28557
LS-9707
Lo-Ten
Lo-ten
Lopac0_000121
Loten
Lotenal
MLS000069622
MLS001066372
MLS001074163
MLS001304038
MolPort-001-792-717
Myocord
NCGC00015007-07
NCGC00015007-13
NCGC00024566-03
NCGC00024566-04
NCGC00024566-05
NCGC00024566-06
NCGC00024566-07
NINDS_000057
Neatenol
Normalol
Normiten
Noten
Oprea1_448775
Oraday
Ormidol
Panapres
Plenacor
Premorine
Prenolol
Prenormine
Prinorm
SAM002564193
SMR000036768
SPBio_001482
SPECTRUM1501127
STK528649
Scheinpharm Atenol
Seles Beta
Seles beta
Selobloc
Serten
Servitenol
Spectrum2_001411
Spectrum3_001448
Spectrum4_000435
Spectrum5_001509
Spectrum_001364
Stermin
Tenidon
Teno-Basan
Teno-basan
Tenobloc
Tenoblock
Tenolol
Tenoprin
Tenoretic
Tenormin
Tenormin (TN)
Tenormine
Tenormine [French]
Tensimin
Tensotin
Tredol
UNII-50VV3VW0TI
Unibloc
Uniloc
Vascoten
Vericordin
Wesipin
Xaten
atenolol
benzeneacetamide, 4-[2'-hydroxy-3
duratenol

Interventional clinical trials:

(show top 50)    (show all 131)
idNameStatusNCT IDPhase
1Ranolazine for the Treatment of Chest Pain in HCM PatientsCompletedNCT01721967Phase 4
2Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human HeartCompletedNCT01798992Phase 4
3Assessment of Wall Thickness in Hypertrophic CardiomyopathyRecruitingNCT02234336Phase 4
4Clinical and Therapeutic Implications of Fibrosis in Hypertrophic CardiomyopathyRecruitingNCT00879060Phase 4
5REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrsRecruitingNCT01803828Phase 4
6Effects of Spironolactone in DialysisRecruitingNCT01128101Phase 4
7Comparing the Effects of Spironolactone With Chlortalidone on LV Mass and Arterial Stiffness in Patients With CKDRecruitingNCT02502981Phase 4
8Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis PatientsRecruitingNCT01503671Phase 4
9Identification of Carnitine-Responsive CardiomyopathyNot yet recruitingNCT01904396Phase 4
10SGLT2 Inhibition and Left Ventricular MassNot yet recruitingNCT02728453Phase 4
11The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve ReplacementSuspendedNCT01375335Phase 4
12Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot StudyTerminatedNCT01272388Phase 4
13Treatment of Preclinical Hypertrophic Cardiomyopathy With DiltiazemCompletedNCT00319982Phase 2, Phase 3
14Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic CardiomyopathyCompletedNCT00821353Phase 3
15Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the HeartCompletedNCT00317967Phase 3
16Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan SyndromeCompletedNCT00723801Phase 3
17Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic CardiomyopathyRecruitingNCT02291237Phase 2, Phase 3
18Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic CardiomyopathyRecruitingNCT00698074Phase 3
19Mobilization of Endothelial Progenitor Cells and AspirinRecruitingNCT02674958Phase 3
20Myocardial Protection With Perhexiline in Left Ventricular HypertrophyRecruitingNCT00989508Phase 2, Phase 3
21Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study).RecruitingNCT02310061Phase 3
22Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart FailureNot yet recruitingNCT02431221Phase 3
23Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic CardiomyopathyCompletedNCT01447654Phase 2
24Perhexiline Therapy in Patients With Hypertrophic CardiomyopathyCompletedNCT00500552Phase 2
25Pirfenidone to Treat Hypertrophic CardiomyopathyCompletedNCT00011076Phase 2
26Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot StudyCompletedNCT00035386Phase 2
27Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)CompletedNCT00001965Phase 2
28A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic CardiomyopathyCompletedNCT00001894Phase 2
29Effect of Losartan in Patients With Nonobstructive Hypertrophic CardiomyopathyCompletedNCT01150461Phase 2
30Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart MuscleCompletedNCT00001960Phase 2
31Study of Blood Flow in Heart MuscleCompletedNCT00001631Phase 2
32Trimetazidine Therapy in Hypertrophic CardiomyopathyRecruitingNCT01696370Phase 2
33CArdiac Desynchronization In Obstructive HCM, CARDIO-HCMRecruitingNCT01332162Phase 2
34Study to Develop a Non-invasive Marker for Monitoring Myocardial FibrosisRecruitingNCT01230918Phase 2
35Hypertrophic Cardiomyopathy Symptom Release by BX1514MRecruitingNCT02590809Phase 2
36Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCMRecruitingNCT01912534Phase 2
37CHANCE - Candesartan in Hypertrophic CardiomyopathyActive, not recruitingNCT00430833Phase 2
38Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly CardiomyopathyNot yet recruitingNCT02611336Phase 2
39Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrsNot yet recruitingNCT02611258Phase 2
40Feasibility Study of Radiofrequency Heating of Cardiac Infarction Scar to Treat Heart FailureTerminatedNCT00881777Phase 1, Phase 2
41Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic CardiomyopathyWithdrawnNCT01556568Phase 2
42Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...CompletedNCT00001396Phase 1
43Single Ascending Dose Study of MYK-461 in Healthy VolunteersCompletedNCT02356289Phase 1
44Biventricular Pacing in Hypertrophic CardiomyopathyRecruitingNCT00504647Phase 1
45Hypertrophic Regression With N-Acetylcysteine in HCMRecruitingNCT01537926Phase 1
46Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate InjectionRecruitingNCT02648009Phase 1
47BNP Testing in Patients With SOB on Presentation to EDRecruitingNCT00163709Phase 1
48Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461Active, not recruitingNCT02329184Phase 1
49Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.CompletedNCT02054221
50Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic CardiomyopathyCompletedNCT01631006

Search NIH Clinical Center for Hypertrophic Cardiomyopathy


Cochrane evidence based reviews: cardiomyopathy, hypertrophic

Genetic Tests for Hypertrophic Cardiomyopathy

About this section

Anatomical Context for Hypertrophic Cardiomyopathy

About this section

MalaCards organs/tissues related to Hypertrophic Cardiomyopathy:

33
Heart, Breast, Lung, Liver, Brain, T cells, Endothelial

Animal Models for Hypertrophic Cardiomyopathy or affiliated genes

About this section

MGI Mouse Phenotypes related to Hypertrophic Cardiomyopathy:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053859.1ACTC1, CSRP3, JPH2, MYBPC3, MYH6, MYH7
2MP:00053698.8ACTC1, CSRP3, JPH2, MYBPC3, MYH6, MYH7

Publications for Hypertrophic Cardiomyopathy

About this section

Articles related to Hypertrophic Cardiomyopathy:

(show top 50)    (show all 1471)
idTitleAuthorsYear
1
De novo variants in sporadic cases of childhood onset schizophrenia. (26508570)
2015
2
Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment. (26541323)
2015
3
MyD88-Dependent Immunity to a Natural Model of Vaccinia Virus Infection Does Not Involve Toll-Like Receptor 2. (24403581)
2014
4
Levels of BNP and stress blood glucose in acute coronary syndrome patients and their relationships with the severity of coronary artery lesion. (23959302)
2014
5
Association of serum and salivary tumor necrosis factor-I+ with histological grading in oral cancer and its role in differentiating premalignant and malignant oral disease. (25227804)
2014
6
Rictor negatively regulates high-affinity receptors for IgE-induced mast cell degranulation. (25378594)
2014
7
Health related quality of life in Iranian hemodialysis patients with viral hepatitis: changing epidemiology. (24032050)
2013
8
A case report of hemosiderosis-induced ventricular pacing exit block. (23907043)
2013
9
Developments in infertility counselling and its accreditation. (23548094)
2013
10
Facial purpura associated with Capnocytophaga canimorsus septicaemia; role of sunlight? (23816547)
2013
11
Candidate gene polymorphisms and the risk for pregnancy-related venous thrombosis. (22533697)
2012
12
Cervicofacial subcutaneous emphysema and pneumomediastinum after retinal detachment surgery: just another monitored anesthesia eye case. (21723109)
2011
13
Soluble IL-2RI+ facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. (21719603)
2011
14
Non-stereo-selective cytosolic human brain tissue 3-ketosteroid reductase is refractory to inhibition by AKR1C inhibitors. (20673851)
2010
15
Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). (19656510)
2010
16
Non-classic cystic fibrosis associated with D1152H CFTR mutation. (19843100)
2010
17
An unusual case of familial ALS and cerebellar ataxia. (20540686)
2010
18
Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction. (19344718)
2009
19
GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. (19684055)
2009
20
Human paraoxonase gene polymorphisms and coronary artery disease risk. (19280995)
2008
21
Microtensile bond strength of adhesive systems to dentin with or without application of an intermediate flowable resin layer. (18438560)
2008
22
Excess casein in the diet is not the unique cause of low-grade metabolic acidosis: role of a deficit in potassium citrate in a rat model. (16407650)
2006
23
Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. (16849400)
2006
24
Life threatening bleeding under adequate oral anticoagulation. Cases 4a, b. (12923579)
2003
25
Regional variation in CCR5-Delta32 gene distribution among women from the US HIV Epidemiology Research Study (HERS). (12140749)
2002
26
Further characterization of the helicase activity of eIF4A. Substrate specificity. (11278350)
2001
27
A case of lymphocutaneous sporotrichosis]. (11479537)
2001
28
Low cerebrospinal fluid hypocretin levels found in familial narcolepsy. (14592396)
2001
29
Comparison of hepatic artery and portal vein reperfusion during orthotopic liver transplantation. (11726832)
2001
30
Von Hippel-Lindau disease masquerading as autosomal dominant polycystic kidney disease. (11273887)
2001
31
The effects of simulated cataract on reading with normal vision and simulated central scotoma. (10755163)
1999
32
The relationship between coagulation time and bilateral occurrence in chronic subdural hematoma]. (10363267)
1999
33
Effect of sphingomyelin and its metabolites on the activity of human recombinant PLC delta 1. (9251249)
1997
34
MR and proton MR spectroscopy of the brain in hyperhomocysteinemia caused by methylenetetrahydrofolate reductase deficiency. (9090418)
1997
35
Geotrichosis of oral mucosa. (9009647)
1996
36
Complement activation by 3-mercapto-1,2-propanediol immobilized on gold surfaces. (8736735)
1996
37
TATA-less promoters of some Ets-family genes are efficiently repressed by wild-type p53. (8957074)
1996
38
Incidence, aetiology, and prognosis of acute epiglottitis in children and adults in Sweden. (8863357)
1996
39
Quantification of intracellular cathepsin activities in human lung tumor cell lines by flow cytometry. (7576237)
1995
40
Renal oncocytoma arising from a renal cyst: a case report and review of the literature. (8189575)
1994
41
Persistent polyclonal B-cell lymphocytosis. (7934138)
1994
42
The Ets transcription factors encoded by the Drosophila gene pointed direct glial cell differentiation in the embryonic CNS. (8033206)
1994
43
Non-isotopic analysis of single strand conformation polymorphism (SSCP) in the exon 13 region of the human dystrophin gene. (8301652)
1993
44
Electrophysiologic studies in birdshot chorioretinopathy. (3177561)
1988
45
Rapidly progressive aortic incompetence in juvenile ankylosing spondylitis: a case report. (6233987)
1984
46
Pseudomyxoma peritonei of ovarian origin--an autopsy case. (161472)
1979
47
48
49
50

Variations for Hypertrophic Cardiomyopathy

About this section

Clinvar genetic disease variations for Hypertrophic Cardiomyopathy:

5 (show all 42)
id Gene Variation Type Significance SNP ID Assembly Location
1MYL3NM_000258.2(MYL3): c.445A> G (p.Met149Val)single nucleotide variantPathogenicrs104893748GRCh37Chr 3, 46901001: 46901001
2MYL3NM_000258.2(MYL3): c.427G> A (p.Glu143Lys)single nucleotide variantPathogenicrs104893750GRCh37Chr 3, 46901019: 46901019
3MYH7NM_000257.3(MYH7): c.1208G> A (p.Arg403Gln)single nucleotide variantPathogenicrs121913624GRCh37Chr 14, 23898487: 23898487
4MYH7NM_000257.3(MYH7): c.2770G> A (p.Glu924Lys)single nucleotide variantLikely pathogenic, Pathogenicrs121913628GRCh37Chr 14, 23893268: 23893268
5MYH7NM_000257.3(MYH7): c.1322C> T (p.Thr441Met)single nucleotide variantPathogenicrs121913653GRCh37Chr 14, 23898249: 23898249
6MYH7NM_000257.3(MYH7): c.1491G> T (p.Glu497Asp)single nucleotide variantLikely pathogenic, Pathogenicrs267606911GRCh37Chr 14, 23897796: 23897796
7MYBPC3NM_000256.3(MYBPC3): c.961G> A (p.Val321Met)single nucleotide variantPathogenicrs200119454GRCh37Chr 11, 47367887: 47367887
8MYBPC3NM_000256.3(MYBPC3): c.3642G> A (p.Trp1214Ter)single nucleotide variantLikely pathogenic, Pathogenicrs368765949GRCh37Chr 11, 47353795: 47353795
9MYBPC3NM_000256.3(MYBPC3): c.1484G> A (p.Arg495Gln)single nucleotide variantLikely pathogenic, Pathogenicrs200411226GRCh37Chr 11, 47364269: 47364269
10MYH7NM_000257.3(MYH7): c.2536G> C (p.Glu846Gln)single nucleotide variantPathogenicrs730880748GRCh37Chr 14, 23894121: 23894121
11TNNI3NM_000363.4(TNNI3): c.407G> A (p.Arg136Gln)single nucleotide variantLikely pathogenic, Pathogenicrs730881069GRCh38Chr 19, 55154172: 55154172
12TCAPNM_003673.3(TCAP): c.208C> T (p.Arg70Trp)single nucleotide variantPathogenicrs775636212GRCh37Chr 17, 37822066: 37822066
13MYBPC3NM_000256.3(MYBPC3): c.2065C> T (p.Gln689Ter)single nucleotide variantLikely pathogenic, Pathogenicrs863224483GRCh38Chr 11, 47339653: 47339653
14MYBPC3NM_000256.3(MYBPC3): c.1091-?_2308+?deldeletionPathogenic
15MYBPC3NM_000256.3(MYBPC3): c.162delGdeletionPathogenicrs864622224GRCh37Chr 11, 47372920: 47372920
16PMPCANM_015160.2(PMPCA): c.1129G> Asingle nucleotide variantPathogenicrs753611141GRCh38Chr 9, 136418847: 136418847
17PMPCANM_015160.2(PMPCA): c.1066G> Asingle nucleotide variantPathogenicrs768643552GRCh37Chr 9, 139313082: 139313082
18JPH2NM_020433.4(JPH2): c.1513G> A (p.Gly505Ser)single nucleotide variantPathogenicrs140740776GRCh37Chr 20, 42744802: 42744802
19CALR3NM_145046.4(CALR3): c.245A> G (p.Lys82Arg)single nucleotide variantPathogenicrs142951029GRCh37Chr 19, 16601330: 16601330
20TPM1NM_001018005.1(TPM1): c.644C> T (p.Ser215Leu)single nucleotide variantLikely pathogenic, Pathogenicrs199476316GRCh37Chr 15, 63354418: 63354418
21MYBPC3NM_000256.3(MYBPC3): c.2308G> A (p.Asp770Asn)single nucleotide variantLikely pathogenic, Pathogenicrs36211723GRCh37Chr 11, 47360071: 47360071
22NM_000257.3(MYH7): c.5135G> A (p.Arg1712Gln)single nucleotide variantLikely pathogenic, Pathogenicrs193922390GRCh37Chr 14, 23884860: 23884860
23MYBPC3NM_000256.3(MYBPC3): c.1235_1236delTT (p.Phe412Terfs)deletionPathogenicrs397515894GRCh37Chr 11, 47364687: 47364688
24MYBPC3NM_000256.3(MYBPC3): c.1504C> T (p.Arg502Trp)single nucleotide variantPathogenicrs375882485GRCh37Chr 11, 47364249: 47364249
25MYBPC3NM_000256.3(MYBPC3): c.1505G> A (p.Arg502Gln)single nucleotide variantLikely pathogenic, Pathogenicrs397515907GRCh37Chr 11, 47364248: 47364248
26MYBPC3NM_000256.3(MYBPC3): c.1624+4A> Tsingle nucleotide variantLikely pathogenic, Pathogenicrs397515916GRCh37Chr 11, 47364125: 47364125
27MYBPC3NM_000256.3(MYBPC3): c.2113dupA (p.Thr705Asnfs)duplicationPathogenicrs397515948GRCh37Chr 11, 47360910: 47360910
28MYBPC3NM_000256.3(MYBPC3): c.2373dupG (p.Trp792Valfs)duplicationPathogenicrs397515963GRCh37Chr 11, 47359281: 47359281
29MYBPC3NM_000256.3(MYBPC3): c.2670G> A (p.Trp890Ter)single nucleotide variantPathogenicrs397515982GRCh37Chr 11, 47357495: 47357495
30MYBPC3NM_000256.3(MYBPC3): c.2905+1G> Asingle nucleotide variantPathogenicrs397515991GRCh37Chr 11, 47356592: 47356592
31MYBPC3NM_000256.3(MYBPC3): c.3192dupC (p.Lys1065Glnfs)duplicationPathogenicrs397516007GRCh37Chr 11, 47354883: 47354883
32MYBPC3NM_000256.3(MYBPC3): c.3330+5G> Csingle nucleotide variantPathogenicrs373746463GRCh37Chr 11, 47354740: 47354740
33MYBPC3NM_000256.3(MYBPC3): c.3697C> T (p.Gln1233Ter)single nucleotide variantPathogenicrs397516037GRCh37Chr 11, 47353740: 47353740
34MYBPC3NM_000256.3(MYBPC3): c.772+1G> Asingle nucleotide variantLikely pathogenic, Pathogenicrs397516072GRCh37Chr 11, 47369974: 47369974
35MYBPC3NM_000256.3(MYBPC3): c.821+1G> Asingle nucleotide variantPathogenicrs397516073GRCh37Chr 11, 47369407: 47369407
36MYBPC3NM_000256.3(MYBPC3): c.772G> A (p.Glu258Lys)single nucleotide variantLikely pathogenic, Pathogenicrs397516074GRCh37Chr 11, 47369975: 47369975
37MYH7NM_000257.3(MYH7): c.1358G> A (p.Arg453His)single nucleotide variantLikely pathogenic, Pathogenicrs397516101GRCh37Chr 14, 23898213: 23898213
38MYH7NM_000257.3(MYH7): c.1988G> A (p.Arg663His)single nucleotide variantLikely pathogenic, Pathogenicrs371898076GRCh37Chr 14, 23896042: 23896042
39TNNI3NM_000363.4(TNNI3): c.434G> A (p.Arg145Gln)single nucleotide variantLikely pathogenic, Pathogenicrs397516349GRCh37Chr 19, 55665513: 55665513
40TNNI3NM_000363.4(TNNI3): c.485G> A (p.Arg162Gln)single nucleotide variantLikely pathogenic, Pathogenicrs397516354GRCh37Chr 19, 55665462: 55665462
41TNNI3NM_000363.4(TNNI3): c.557G> A (p.Arg186Gln)single nucleotide variantPathogenicrs397516357GRCh37Chr 19, 55663278: 55663278
42MYBPC3NM_000256.3(MYBPC3): c.1624G> C (p.Glu542Gln)single nucleotide variantLikely pathogenic, Pathogenicrs121909374GRCh37Chr 11, 47364129: 47364129

Expression for genes affiliated with Hypertrophic Cardiomyopathy

About this section
Search GEO for disease gene expression data for Hypertrophic Cardiomyopathy.

Pathways for genes affiliated with Hypertrophic Cardiomyopathy

About this section

Pathways related to Hypertrophic Cardiomyopathy according to KEGG:

31
id Name KEGG Source Accession
1Hypertrophic cardiomyopathy (HCM)hsa05410

Pathways related to Hypertrophic Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 13)
idSuper pathwaysScoreTop Affiliating Genes
110.3MYH7, MYL2
210.2MYL3, TNNI3, TNNT2
310.2MYH6, MYH7, PRKAG2
4
Show member pathways
10.2MYH6, MYH7, MYL2, MYL3
5
Show member pathways
10.1ACTC1, MYH6, MYH7, MYL2, MYL3
6
Show member pathways
10.1MYH6, MYH7, MYL2, MYL3, MYO6
7
Show member pathways
10.1MYH6, MYH7, MYL2, MYL3, MYO6
810.1ACTC1, MYH6, MYL2, TNNI3, TNNT2
99.8ACTC1, MYH6, MYH7, MYL2, MYL3, TNNI3
109.6ACTC1, MYBPC3, MYH6, MYL2, MYL3, TCAP
11
Show member pathways
9.6ACTC1, MYH6, MYH7, MYL2, MYL3, PLN
12
Show member pathways
9.6MYBPC3, MYH6, MYL2, MYL3, PLN, TCAP
13
Show member pathways
9.4ACTC1, MYBPC3, MYH6, MYH7, MYL2, MYL3

GO Terms for genes affiliated with Hypertrophic Cardiomyopathy

About this section

Cellular components related to Hypertrophic Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1myofibrilGO:003001610.8TNNT2, TPM1
2myosin complexGO:001645910.7MYL2, MYL3, MYO6
3cytosolGO:00058299.9ACTC1, MYBPC3, MYL2, MYL3, TNNT2, TPM1

Biological processes related to Hypertrophic Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1regulation of striated muscle contractionGO:000694210.8MYL2, MYL3
2negative regulation of ATPase activityGO:003278010.6PLN, TNNI3
3skeletal muscle thin filament assemblyGO:003024010.6ACTC1, TCAP
4cardiac muscle fiber developmentGO:004873910.6MYH6, TCAP
5sarcomerogenesisGO:004876910.5TCAP, TTN
6heart contractionGO:006004710.5ACTC1, MYL2, TNNI3
7ATP metabolic processGO:004603410.5MYH6, MYH7
8striated muscle contractionGO:000694110.4MYH7, TNNI3
9sarcomere organizationGO:004521410.3MYH6, TTN
10cardiac myofibril assemblyGO:005500310.3ACTC1, CSRP3, MYL2, TCAP, TTN
11positive regulation of ATPase activityGO:003278110.2MYBPC3, TNNT2, TPM1
12muscle filament slidingGO:003004910.1ACTC1, MYBPC3, MYH6, MYH7, MYL3, TCAP
13cardiac muscle contractionGO:00600489.5MYH6, MYL2, MYL3, TCAP, TNNI3, TNNT2

Molecular functions related to Hypertrophic Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1motor activityGO:000377410.6MYH7, MYL3
2protein kinase bindingGO:001990110.2MYH6, PRKAG2, TNNI3
3actin bindingGO:00037799.9MYBPC3, TNNT2, TPM1

Sources for Hypertrophic Cardiomyopathy

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet